PP
PTGX icon

Paloma Partners’s Protagonist Therapeutics PTGX Stock Holding History

Paloma Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-55,499
Closed -$373K – 1870
2018
Q2 		$373K Buy
+55,499
New +$426K 0.01% 1169

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Paloma Partners's PTGX Position: Q3 2018 in Review

Paloma Partners sold out of Protagonist Therapeutics (PTGX) in Q3 2018, closing a stake of 55,499 shares — an estimated $373K sold.

Paloma Partners first reported a position in PTGX in Q2 2018 and held it in 1 quarter. The position peaked at $373K in Q2 2018. 61 funds tracked by Wall St. Rank hold PTGX as of Q3 2018.

  • Paloma Partners reported no remaining Protagonist Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Paloma Partners sold 55,499 Protagonist Therapeutics shares in Q3 2018, an estimated $373K.
  • Paloma Partners first reported a position in Protagonist Therapeutics in Q2 2018 and held it in 1 quarter.
  • Paloma Partners's Protagonist Therapeutics position peaked at $373K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.